William Blair analyst Sami Corwin has maintained their bullish stance on CRSP stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sami Corwin’s rating is based on the promising results from the Phase I clinical trial of CRISPR Therapeutics’ CTX310. The trial demonstrated significant reductions in ANGPTL3 protein levels, which are linked to improved lipid biomarkers, including LDL cholesterol and triglycerides.
The therapy showed dose-dependent efficacy, with the highest dose group achieving substantial reductions in LDL cholesterol and triglycerides, indicating potential for addressing dyslipidemia in patients unresponsive to standard treatments. These compelling clinical outcomes support a positive outlook for CRISPR Therapeutics, justifying the Buy rating.
According to TipRanks, Corwin is a 5-star analyst with an average return of 25.7% and a 54.82% success rate. Corwin covers the Healthcare sector, focusing on stocks such as Solid Biosciences, Ultragenyx Pharmaceutical, and uniQure.
In another report released today, Needham also reiterated a Buy rating on the stock with a $81.00 price target.